From the Editors
In the October issue of The Oncology Pharmacist, we feature highlights from the recent Hematology/Oncology Pharmacy Association (HOPA)’s Oncology Pharmacy Practice Management Program, including an article on the challenges of managing patients with non–small-cell lung cancer (NSCLC) associated with ALK mutations. At HOPA, Jim M. Koeller, MS, Professor, College of Pharmacy, The University of Texas at Austin, discussed the current treatment guidelines for this patient population, emphasizing the need for pharmacist inclusion during testing for ALK mutations.
As always, we hope you will enjoy this issue of TON and look forward to receiving your feedback.
Results 1 - 10 of 56